Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B‐cell lymphoma
Authors:
Open Access
- 28 October 2021
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 97 (1) , E14-E17
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81770213)
- Natural Science Foundation of Tianjin Municipality (18JCZDJC45100, 19JCYBJC26500)
This publication has 6 references indexed in Scilit:
- Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network reportBlood, 2020
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyJournal of Clinical Oncology, 2019
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesNature Medicine, 2018
- Genetic and Functional Drivers of Diffuse Large B Cell LymphomaCell, 2017
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint BlockadeCell, 2016